Download App

Log in to access Online Inquiry
Company Overview More
Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners. The company's development drug candidates include Enobosarm, an oral selective androgen receptor agonist that is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Sabizabulin, which is phase IIb clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Enobosarm + abemaciclib combination therapy, which is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; and Sabizabulin + enobosarm combination therapy, an oral targeted cytoskeleton disruptor plus selective androgen receptor agonist, which is in phase II clinical trial for the treatment of metastatic triple negative breast cancer. Its drug candidates also comprise Sabizabulin, which is in Phase II clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer; VERU-100, a GnRH antagonist peptide injection, which is in Phase II clinical trial for the treatment of advanced hormone sensitive prostate cancer; Zuclomiphene Citrate, which is in Phase II clinical trial for treating hot flashes; and Sabizabulin, which is in phase III clinical trial for the treatment of SARS-CoV-2 in subjects at high risk for acute respiratory distress syndrome. In addition, the company is advancing a new drug formulation for the treatment of men with lower urinary tract symptoms from an enlarged prostate. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.
CEO: Steiner F.A.C.S, F.A.C.S., M.D., Mitchell S.
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Moomoo > Quotes > VERU Veru Inc > Detailed Quotes

VERU Veru Inc

15.010-0.590-3.78%
Close 05/18 20:00 ET
14.410-0.6-4.00%
Post Mkt Price 05/18 19:59 ET
High
16.370
Open
15.940
Turnover
398.00M
Low
13.720
Pre Close
15.600
Volume
26.69M
Market Cap
1.20B
P/E(TTM)
Loss
52wk High
17.500
Shares
80.07M
P/E(Static)
166.78
52wk Low
4.340
Float Cap
782.03M
Bid/Ask %
-5.88%
Historical High
24.570
Shs Float
52.10M
Volume Ratio
0.51
Historical Low
0.271
Dividend TTM
--
Div Yield TTM
--
P/B
8.84
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
51.22%
Amplitude
16.99%
Avg Price
14.914
Lot Size
1
Float Cap
782.03M
Bid/Ask %
-5.88%
Historical High
24.570
Shs Float
52.10M
Volume Ratio
0.51
Historical Low
0.271
Dividend TTM
--
P/B
8.84
Dividend LFY
--
Turnover Ratio
51.22%
Amplitude
16.99%
Avg Price
14.914
Lot Size
1
Price Forecast

No Data

News

Comment